LAMIVUDINE; STAVUDINE; NEVIRAPINE
Clinical safety rating: safe
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with natural substrate and causing chain termination. Stavudine is an NRTI that inhibits HIV-1 reverse transcriptase after intracellular phosphorylation to its active triphosphate form. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition.
| Metabolism | Lamivudine is minimally metabolized (5-10%) via hepatic oxidation; primarily excreted unchanged in urine. Stavudine is metabolized by phosphorylation to active triphosphate; also undergoes glucuronidation and oxidation, with 40% excreted unchanged in urine. Nevirapine is extensively metabolized by cytochrome P450 (CYP3A4 and CYP2B6) to hydroxylated metabolites, which undergo glucuronidation. |
| Excretion | Lamivudine: ~70% renal (glomerular filtration and tubular secretion), ~30% unchanged; Stavudine: ~40% renal (tubular secretion), ~60% metabolized to inactive metabolites; Nevirapine: ~80% renal (metabolites, <5% unchanged), ~10% fecal. |
| Half-life | Lamivudine: 5-7 h (prolonged in renal impairment); Stavudine: 1.6 h (prolonged in renal impairment, ~3.5-8 h in ESRD); Nevirapine: ~45 h (single dose), ~25-30 h (multiple doses due to autoinduction; prolonged in hepatic impairment). |
| Protein binding | Lamivudine: <36% (albumin); Stavudine: negligible (<10%); Nevirapine: ~60% (albumin). |
| Volume of Distribution | Lamivudine: 1.3 L/kg (extensive distribution, including CSF); Stavudine: 0.5-0.7 L/kg (distribution into CSF ~40% of plasma); Nevirapine: 1.2-1.5 L/kg (highly lipophilic, penetrates CSF and breast milk). |
| Bioavailability | Lamivudine: oral ~86%; Stavudine: oral ~86%; Nevirapine: oral >90%. |
| Onset of Action | Lamivudine: rapid antiviral effect within hours; Stavudine: antiviral effect detectable within days; Nevirapine: rapid absorption, drug levels reach steady-state in 2-4 weeks due to autoinduction. |
| Duration of Action | Lamivudine: dosing Q12h (Q24h in renal impairment), antiviral effect persists with consistent dosing; Stavudine: dosing Q12h; Nevirapine: dosing Q12h, autoinduction leads to lower troughs if steady-state not achieved. |
One tablet containing lamivudine 150 mg, stavudine 30 mg (or 40 mg if weight ≥60 kg), and nevirapine 200 mg orally twice daily.
| Dosage form | TABLET |
| Renal impairment | For CrCl <50 mL/min: not recommended as a fixed-dose combination. Individual components require dose adjustment: lamivudine: CrCl 30-49 mL/min: 150 mg first dose then 100 mg daily; CrCl 15-29 mL/min: 150 mg first dose then 50 mg daily; CrCl 5-14 mL/min: 150 mg first dose then 25 mg daily; CrCl <5 mL/min: 50 mg first dose then 25 mg daily. Stavudine: CrCl 26-50 mL/min: 15 mg every 12 hours (or 20 mg if ≥60 kg); CrCl 10-25 mL/min: 15 mg every 24 hours (or 20 mg if ≥60 kg). Nevirapine: no adjustment required. |
| Liver impairment | Contraindicated in Child-Pugh Class B or C due to nevirapine hepatotoxicity. For mild hepatic impairment (Child-Pugh Class A): use with caution; no specific dose adjustment defined. |
| Pediatric use | Weight-based dosing for fixed-dose combination: For children weighing 14-24 kg: 1 tablet (lamivudine 150 mg/stavudine 30 mg/nevirapine 200 mg) twice daily; 25-59 kg: 2 tablets twice daily; ≥60 kg: adult dose. Note: Stavudine component weight-based: 1 mg/kg/dose twice daily. Lamivudine: 4 mg/kg/dose twice daily. Nevirapine: lead-in dosing 120 mg/m² once daily for 14 days, then 120 mg/m² twice daily (max 200 mg/dose). |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
| FDA category | Animal |
| Breastfeeding | Lamivudine: excreted into breast milk at concentrations similar to maternal serum (M/P ratio ~1.0); limited data on infant levels. Stavudine: excreted into breast milk; M/P ratio 0.9; infant exposure 2-4% of therapeutic dose. Nevirapine: extensively excreted (<1-1.2% maternal dose); M/P ratio 0.7. WHO advises breastfeeding while on ART with viral suppression; manufacturer advises caution due to potential for adverse effects. |
| Teratogenic Risk |
■ FDA Black Box Warning
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine and stavudine. Nevirapine can cause severe, life-threatening hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure, and severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions.
| Common Effects | Peripheral neuropathy |
| Serious Effects |
Concomitant use with other NNRTIs (e.g., efavirenz) due to lack of efficacy; hypersensitivity to any component; severe hepatic impairment (Child-Pugh class C) for nevirapine; coadministration with drugs that cause serious adverse reactions via CYP3A4 induction/inhibition
| Precautions | Monitor for lactic acidosis and hepatotoxicity, particularly in patients with risk factors (e.g., obesity, prolonged nucleoside exposure). Nevirapine: hepatic adverse events, severe skin reactions, and immune reconstitution syndrome. Lamivudine: exacerbation of hepatitis B upon discontinuation. Stavudine: peripheral neuropathy, pancreatitis, and lipodystrophy. |
Loading safety data…
| No specific geriatric dose; monitor renal function due to age-related decline. Use individual components if CrCl <50 mL/min. |
| Lamivudine: FDA pregnancy category C; crosses placenta; no significant increase in birth defects in first trimester exposure across multiple registries. Stavudine: FDA pregnancy category C; animal studies show toxicity; human data limited but no teratogenicity signals. Nevirapine: FDA pregnancy category B for single dose; C for continuous use; no teratogenicity in humans; risk of hepatotoxicity in pregnant women with CD4 >250. All trimesters: increased risk of fetal lactic acidosis and mitochondrial toxicity in combination. Overall: low teratogenic risk, but consider alternatives. |
| Fetal Monitoring | Maternal: LFTs, bilirubin, amylase, lipase, CBC, CD4 count, viral load (HIV RNA), ANC, serum lactate (if symptoms). Fetal: ultrasound for growth parameters, anatomy scan, and fetal monitoring for LFT elevations or acidosis. Newborn: HIV testing (PCR) at birth, 6 weeks, and 4-6 months; monitor for hyperlactatemia. |
| Fertility Effects | No known negative impact on fertility; antiretroviral therapy improves overall health and may restore fertility. Animal studies show no adverse effects on reproduction. Nevirapine may cause hepatotoxicity but no direct gonadal toxicity. |
| Food/Dietary | No significant food interactions. Take without regard to meals. Avoid alcohol and high-fat meals in HIV patients due to general GI tolerance. |
| Clinical Pearls | Monitor for hepatotoxicity and skin reactions (e.g., Stevens-Johnson syndrome) especially within first 18 weeks of nevirapine. Lactic acidosis and hepatic steatosis are rare but serious with lamivudine + stavudine. Peripheral neuropathy from stavudine is dose-dependent; switch to tenofovir if severe. Do not restart nevirapine after severe hypersensitivity. Check renal function before starting lamivudine (CrCl <50 mL/min requires dose adjustment). |
| Patient Advice | Take at the same time daily with or without food. · Report immediately any rash, fever, blisters, or mouth sores (signs of hypersensitivity). · Numbness, tingling, or pain in hands/feet may occur; notify your doctor. · Do not stop or change dose without consulting your doctor. · Use effective barrier contraception; this regimen does not prevent HIV transmission. · Avoid alcohol and acetaminophen >2g/day due to increased hepatotoxicity risk. · Store at room temperature away from moisture and heat. |